文献速递乳腺癌放疗放疗物理与技术

乳腺癌大分割放疗:2008至2017年美国财务风险与支出

Hypofractionated Radiation Therapy for Breast Cancer: Financial Risk and Expenditures in the United States, 2008 to 2017.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-10-09

该回顾性研究基于2008至2017年商业保险理赔数据,比较早期乳腺癌保乳术后大分割全乳照射(HF-WBI)与常规全乳照射(CF-WBI)的支出,发现HF-WBI使用率上升且保险方与患者支出均更低,但使用率存在地理差异且无证据显示经济障碍减缓其推广。

要点

  • HF-WBI保险方平均放疗支出较CF-WBI显著更低,调整后差异为6375美元。
  • HF-WBI患者自付支出平均比CF-WBI少139美元。
  • HF-WBI使用率存在地理差异(范围9.6%-36.2%),与经济激励无一致关系。

核心结论

  • 若趋势持续,HF-WBI将很快成为美国乳腺放疗的主导形式。
  • HF-WBI为医疗系统和患者节省显著费用,但无证据表明经济障碍减缓其推广。

研究设计与样本

  • 回顾性研究,使用2008至2017年私营雇主商业保险理赔数据,对接受放疗的商业保险患者进行汇总横截面评估。
  • 研究人群为接受肿块切除术和全乳照射的早期乳腺癌女性患者。

主要发现

  • 共15869名女性接受HF-WBI,59328名接受CF-WBI。
  • HF-WBI使用率从2008年至2017年增加。
  • 社区层面因素如大学毕业生比例较高和种族构成更多样与HF-WBI使用增加相关。
  • HF-WBI保险方平均放疗支出显著低于CF-WBI(调整后差异6375美元;95%CI 6147-6603美元)。
  • HF-WBI患者平均自付支出比CF-WBI少139美元。

关键数值与推荐

  • HF-WBI与CF-WBI保险方支出调整后差异为6375美元(95%CI 6147-6603美元)。
  • HF-WBI患者自付支出平均比CF-WBI少139美元。
  • HF-WBI使用率地理范围为9.6%-36.2%。

临床怎么用

  • HF-WBI可显著降低保险方和患者的放疗支出。
  • 促进HF-WBI采用需多层面方法,包括个人、社区和卫生政策。
  • 政策创新可考虑非财务激励以推广HF-WBI使用。

局限性

  • 研究基于商业保险理赔数据,可能不涵盖无保险或其他保险类型患者。
  • 回顾性设计可能存在未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Rising cancer care expenditures and technological advancement of shorter radiation therapy regimens have drawn significant attention to the use of hypofractionated radiation therapy in clinical care. We examine the costs of hypofractionated whole breast irradiation (HF-WBI) compared with conventional whole breast irradiation (CF-WBI) in the United States and investigate the influences of patient characteristics and commercial insurance on HF-WBI use. METHODS AND MATERIALS: In a retrospective study using private employer-sponsored insurance claims, a pooled cross-sectional evaluation of radiation therapy in patients with commercial insurance was performed from 2008 to 2017. The study population included female patients with early-stage breast cancer treated with lumpectomy and whole breast irradiation. RESULTS: A total of 15,869 women received HF-WBI, and 59,328 received CF-WBI. HF-WBI use increased from 2008 to 2017. Community-level factors such as a higher proportion of college graduates and greater mixed racial composition were associated with increased HF-WBI use. Mean insurer-paid radiation therapy expenditures were significantly lower for HF-WBI versus CF-WBI (adjusted difference, $6375; 95% confidence interval, $6147-$6603). Mean patient out-of-pocket expenditure for HF-WBI was $139 less than that for CF-WBI. Geographic variation existed across the United States in HF-WBI use (range, 9.6%-36.2%), with no consistent relationship between HF-WBI use and corresponding average cost differences between HF-WBI and CF-WBI. CONCLUSIONS: If trends continue, HF-WBI will soon become the dominant form of radiation treatment in the United States. Although HF-WBI represents significant savings to the health care system and individual patients, no evidence indicated that a financial disincentive had slowed adoption of HF-WBI. Therefore, multilevel approaches, including individuals, the community, and health policy, should be used to promote cost-effective cancer care. Innovations to policies on cost-effective radiation therapy treatment might consider non-financial incentives to promote HF-WBI use.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Saulsberry L, Liao C, Huo D, et al. Hypofractionated Radiation Therapy for Breast Cancer: Financial Risk and Expenditures in the United States, 2008 to 2017. Int J Radiat Oncol Biol Phys. 2021. PMID: 34637883. doi:10.1016/j.ijrobp.2021.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。